At ECTRIMS 2025, the professor of neurology at Karolinska Institutet provided clinical insights on results from the phase 3 RIDOSE-MS trial of yearly rituximab in relapsing-remitting multiple sclerosis. [WATCH TIME: 5 minutes]
Anders Svenningsson, MD, PhD
Advertisement
Articles by Anders Svenningsson, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Gene Therapy AMT-130 Meets Endpoints in Huntington Study, FDA Submission to Follow
2
Phase 2a INFORM-MS Trial to Study Anti-CD3 Agent Foralumab in Nonactive Secondary Progressive MS
3
Tolebrutinib Preserves Notable MS Quality-of-Life Features in Nonrelapsing Secondary Progressive Multiple Sclerosis
4
Latest Updates and Future Directions in Multiple Sclerosis Care: Kathleen Costello, CRNP, MSCN
5
